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Background
The genetic diversity of HIV-1, particularly in Env, is con-
sidered a major challenge for vaccine researchers, espe-
cially those attempting to elicit broadly neutralizing
antibodies. Categorizing HIV strains into neutralization
serotypes may help determine the requirements for maxi-
mal vaccine immune coverage. HIV is divided into clades,
based on genetic relatedness, principally in Env. Investiga-
tions as to whether these clades might help to define neu-
tralizing serotypes have so far mostly been confined to
small studies, and have been hampered by the challenges
of traditional PBMC-blast neutralization assays. The
observation that some HIV+ plasmas neutralize viruses
from several major clades hints of an undercurrent of con-
served neutralization, but its potency relative to any clade-
restricted activity is unknown. High throughput pseudovi-
rus neutralization assays provide a way to investigate.
Methods
Here, we measured neutralization of 45 primary viruses
from clades B, C and CRF_01 AE by 12 broad plasmas
from the same 3 clades.
Results
Significant cross-neutralization was observed, and well-
defined neutralizing serotypes was absent. However, each
plasma exhibited a unique pattern against the spectrum of
viruses. Increased intraclade neutralization titers was
observed in many cases. These were most pronounced for
clade B-E viruses that were neutralized 2–10 fold more
potently by clade-matched plasmas in several cases. We
also investigated binding serotypes by gp120 ELISA,
where we observed greater intraclade binding titers for B-
E plasmas, mirroring the intraclade neutralization. Map-
ping analyses suggested that in some cases, the cross-neu-
tralizing activity is mostly directed to gp120 and overlaps
the CD4 binding site.
Conclusion
The generally broad neutralization observed suggests that
an immunogen based on one or a few Envs could, in prin-
ciple, provide worldwide HIV-1 protection. Clade C Envs
may be worth special attention, considering the particu-
larly broad plasma neutralizing activities. The challenge
remains to better define the cross-neutralizing specificities
and moreover, to find immunogens able to induce them.
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